Welcome to our dedicated page for Processa Pharmaceuticals news (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals stock.
Processa Pharmaceuticals develops clinical-stage therapies centered on Next Generation Cancer (NGC) drug products. Company news commonly covers NGC-Cap, its lead oncology asset combining PCS6422 with capecitabine, including clinical updates in advanced or metastatic breast cancer and disclosures on metabolite exposure, safety profile and therapeutic-index objectives.
Updates also address the company's broader pipeline and business priorities, including PCS499 for focal segmental glomerulosclerosis, partnership activity for non-oncology assets, capital actions, conference participation, governance matters and operating or financial results tied to its development-stage biotechnology model.
Processa Pharmaceuticals (Nasdaq: PCSA) will present its strategic focus at the Biotech Showcase on January 11, 2023, at 10 AM. CEO Dr. David Young will detail the company's therapeutic direction and engage with potential investors during the J.P. Morgan Annual HealthCare Conference week. The firm aims to meet the needs of patients with unmet conditions through its clinical pipeline, including treatments for various cancers and gastrointestinal disorders. Forward-looking statements highlight possible risks and uncertainties in achieving future milestones.
Processa Pharmaceuticals (Nasdaq: PCSA) reported positive results from a Phase 2A study of PCS12852 for treating gastroparesis. The 0.5 mg daily dose over 28 days significantly improved symptoms, with a greater percentage of patients achieving clinically meaningful reductions compared to placebo. Notably, 100% of patients on the 0.5 mg dose saw improvements. The study also indicated that longer treatment durations may yield even better results. These findings support the initiation of a Phase 2B trial in 2023.
Processa Pharmaceuticals (PCSA) reports positive preliminary results for PCS12852, which shows a significant effect on gastric emptying rates, leading to a Phase 2B trial planned for 2023. Additionally, the Next Generation Capecitabine (PCS6422) has identified effective dosing regimens for its Phase 2B trial after a successful FDA meeting. Financially, the company reported a net loss of $14.4 million for the nine months ending September 30, 2022, with cash reserves of $9.1 million, projected to fund operations into Q3 2023.
Processa Pharmaceuticals (PCSA) announced positive results from its Phase 2A Proof-of-Concept trial for PCS12852, a treatment for gastroparesis. The trial demonstrated a statistically significant improvement in gastric emptying among patients receiving a 0.5 mg dose compared to placebo, with a p-value of 0.10. Adverse events were mild to moderate, with no serious cardiovascular issues reported. Processa plans to evaluate PCS12852's effects on gastroparesis symptoms by year-end and initiate a Phase 2B trial in 2023.
Processa Pharmaceuticals (Nasdaq: PCSA) will hold a conference call on November 8, 2022, at 4:30 p.m. EST to discuss its Q3 2022 results and provide updates on its clinical pipeline. Interested participants can join via toll-free number 888-506-0062 or through an online webcast. The company focuses on developing treatments for patients with unmet medical needs, with ongoing clinical programs including PCS6422 for cancer and PCS499 for ulcerative necrobiosis lipoidica.
Processa Pharmaceuticals (PCSA) announced positive outcomes from its ongoing Next Generation Capecitabine (NGC) Phase 1B trial. The NGC dosage regimens demonstrated significantly higher potency than existing FDA-approved capecitabine, with a 5-FU systemic exposure approximately 50 times greater. The trial showed reduced conversion of 5-FU into side-effect-causing metabolites, with less than 10% being converted compared to 80% for traditional capecitabine. In 2023, Processa plans to engage the FDA regarding its Phase 2B trial design to evaluate improved efficacy-safety profiles.
Processa Pharmaceuticals (Nasdaq: PCSA) announced significant advancements in its clinical trials, including the early completion of enrollment for PCS12852 for gastroparesis, with data expected by year-end. The company is expanding its trial sites for PCS6422 and PCS499, enhancing patient awareness and enrollment efforts. These initiatives are aimed at improving treatment options for conditions with unmet medical needs. Critical data on DPD formation and safety profiles will be available soon, with further development anticipated in 2023.
Processa Pharmaceuticals, a clinical stage biopharmaceutical company (Nasdaq: PCSA), announced that CEO Dr. David Young will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2022. A live webcast of the presentation will be available on the company’s investor relations page. Processa focuses on developing treatments for patients with unmet medical needs, with an active pipeline including PCS6422 for metastatic cancers, PCS499 for ulcerative necrobiosis lipoidica, and PCS12852 for GI motility disorders. For more information, visit www.processapharma.com.
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has appointed Khoso Baluch and James Neal as Independent Directors to its Board, effective August 2022. Current board member Justin Yorke has been named Chairman. Yorke emphasized the board's focus on three ongoing clinical trials and five pipeline products. Baluch brings over 36 years of biopharmaceutical experience, while Neal has over 25 years in business and technology collaborations. CEO Dr. David Young expressed confidence in their backgrounds to enhance the company’s trajectory as it aims to address unmet medical needs.
Processa Pharmaceuticals (Nasdaq: PCSA) reported financial results for the quarter ended June 30, 2022, highlighting a net loss of $8.4 million ($0.53 per share), up from $5.3 million in the same period last year. The company has a cash balance of $12.1 million, sufficient to fund operations into Q3 2023. Key developments include anticipated completion of enrollment for PCS12852 and progress in trials for PCS6422 and PCS499, with enrollment efforts yielding positive patient activity. Increased clinical trial costs are expected due to ongoing developments.